Telmisartan Modestly Reduces Major Cardiovascular Events In Patients Unable To Tolerate Ace Inhibitors (Transcend Study)
September 1st, 2008 by 
admin The angiotensin-receptor medication (ARB) telmisartan should be regarded as a possibleness communication for tube disease or high-risk diabetes, in the 20% of patients who are unable to tolerate the accepted communication of angiotensin-converting enzyme (ACE) inhibitors.
Posted in Cardiology | 